IOV-EAP-402
Expanded Access Program of AMTAGVI that is Out of Specification for Commercial Release
The objective of this expanded access protocol is to provide access to Out of Specification (OOS) AMTAGVI treatment to patients. This program provides access to OOS AMTAGVI (lifileucel) that does not meet commercial release criteria but does meet Iovance clinical trial release criteria. Patients will be followed for safety and efficacy.